2018 American Transplant Congress
Absence of Rejection in a Facial Allograft Recipient with a Postive Flow Crossmatch 24 Months after Induction with Rabbit Anti-Thymocyte Globulin and Anti-CD20+ Monoclonal Antibody
OBJECTIVE: Vascularized composite allograft (VCA) transplantation has become a feasible reconstructive option for patients with severe facial disfigurement. Short term patient and graft survival have…2018 American Transplant Congress
The Ratio of CTLA4 to Perforin and Granzyme B as a Potential Biomarker of Tolerance in Chimeric Renal Transplant Patients
Background: Thirty-six subjects have been enrolled in a phase II clinical trial aimed to induce tolerance through chimerism. Each subject received FCRx (mPBMC enriched in…2018 American Transplant Congress
Target Tacrolimus Troughs and CYP3A5 Polymorphisms Do Not Predict Therapeutic Drug Exposure in African American and Caucasian Renal Transplant Recipients
Background: African American(AA) renal transplant recipients(RTR) require larger tacrolimus(TAC) doses to achieve similar troughs to Caucasians which may be due to CYP3A5 polymorphisms. TAC pharmacokinetics…2018 American Transplant Congress
The Impact of Conversion from Immediate Release Twice-Daily Tacrolimus (Prograf®) to Once-Daily Extended Release Tacrolimus (Envarsus®) in Liver Transplant Recipients
The safety and efficacy of substitution with a novel once-daily extended-release tacrolimus (LCPT;Envarsus®)to immediate-release tacrolimus (IR-Tac, Prograf®) twice daily in liver transplant patients have not…2018 American Transplant Congress
Diagnosis and Prevalence of Strongyloidiasis in Solid Organ Transplant Patients
Background: Immunosuppression of a host with chronic Strongyloides stercoralis infection can lead to dissemination, with a fatality rate of up to 85%. Screening for S.…2018 American Transplant Congress
Designing Novel Selective Immunoproteasome Inhibitors Reveals a Critical Role of the Immunoproteasome in Protecting Antibody Secreting B Cells from Apoptosis
Constitutive proteasomes (c-20S) are ubiquitously-expressed cellular proteases that degrade polyubiquitinated proteins and regulate cell functions. Its inhibitor, bortezomib, is a plasma cell-targeted therapy used in…2018 American Transplant Congress
Tissue Talks: Graft´s Histological Findings 10 Years after Belatacept or CNI
The BENEFIT study demonstrated that 7 yrs after kidney transplantation (KT), mean eGFR, patient and graft survival, were significantly higher in the belatacept group than…2018 American Transplant Congress
Transplantation Tolerance Prevents CMV Reactivation and Preserves Kidney Allograft Function in a D+/R- Transplant Setting
Background: Immune responses to cytomegalovirus (CMV) infection may precipitate acute/chronic graft rejection in immunocompromised transplant recipients. CMV infection can be primary or its reactivation from…2018 American Transplant Congress
Patients Converted to Belatacept Show Different Immunophenotyping Compared with De Novo Belatacept-Treated Patients
The incidence of adverse clinical events mainly in early, but not late post-transplantation such as an increased rate of acute rejection precludes the use of…2018 American Transplant Congress
Effect of Everolimus on Body Composition; 1-Year after Kidney Transplantation
【Background】Weight gain, and especially visceral fat gain early after kidney transplantation has a worse outcome for metabolic disorder, graft function, and cardiovascular disease. The mammalian…
- « Previous Page
- 1
- …
- 79
- 80
- 81
- 82
- 83
- …
- 138
- Next Page »